GSK and Galapagos go separate ways on once-hyped anti-infective alliance
This article was originally published in Scrip
It emerged at an R&D update provided by the Belgian biotech firm Galapagos this week that the potentially high-value anti-infectives alliance it established with GlaxoSmithKline in 2007 was dissolved last year. Galapagos took back rights to the antibacterial programmes and GSK retained those for the viral programmes in a split which Galapagos CEO Onno van de Stolpe said was prompted by Galapagos deciding that the costs of the alliance were unsustainable on its part.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.